U.S. Autoimmune Disease Diagnostics Market To Reach $3.01 Billion By 2030

U.S. Autoimmune Disease Diagnostics Market Growth & Trends

The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques aresignificantly driving the growth of the market.

Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.

The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.

 Request a free sample copy or view report summary: U.S. Autoimmune Disease Diagnostics Market Report

U.S. Autoimmune Disease Diagnostics Market Report Highlights

• Localized autoimmune disease diagnostics type dominated the market with a 66.0% share in 2023 owing to the rising advanced imaging techniques, such as ultrasound, MRI, and PET scans, which allow for detailed visualization of affected tissues or organs.

• The antinuclear antibody test type segment held the largest market share in 2023 and is anticipated to witness the fastest growth over the forecast period.

• The hospitals end-use segment dominated the market in 2023 owing to the growingneed for accurate and precise testing methods.

• In November 2023, Progentec Diagnostics and Mayo Clinic Laboratories announced a strategic partnership to commercialize Progentec’s range of patented biomarker blood tests for the early detection and treatment of autoimmune disorders. The partnership seeks to improve accessibility for patients and clinicians in the United States and a few international markets. 

U.S. Autoimmune Disease Diagnostics Market Segmentation

Grand View Research has segmented the U.S. autoimmune disease diagnostics market based on type, test type, end use, and region:

U.S. Autoimmune Disease Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Systemic Autoimmune Disease Diagnostics

  • Rheumatoid Arthritis

  • Ankylosing Spondylitis Diagnostics

  • Systemic Lupus Erythematosus (SLE)

  • Others

• Localized Autoimmune Disease Diagnostics

  • Multiple Sclerosis

  • Type 1 Diabetes

  • Hashimoto's Thyroiditis

  • Idiopathic Thrombocytopenic Purpura

  • Others

U.S. Autoimmune Disease Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Antinuclear Antibody Tests

• Autoantibody Tests

• C-Reactive Protein (CRP)

• Complete Blood Count (CBC)

• Urinalysis

• Others

U.S. Autoimmune Disease Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Diagnostic Centers

• Others

U.S. Autoimmune Disease Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Autoimmune Disease Diagnostics Market

• Abbott Laboratories

• Biomerieux

• Trinity Biotech

• Bio-rad Laboratories

• Thermo Fisher Scientific

• BD Biosciences

• Beckman Coulter

• F. Hoffmann-La Roche Ltd.

• Quest Diagnostics Inc.

• Siemens Healthcare GmbH

• Werfen